Lapatinib Al

Lapatinib, the active ingredient in Lapatinib Al, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of HER2‑positive metastatic breast cancer and HER2‑positive gastric cancer in adult patients. The drug targets specific cellular pathways that drive tumor growth, offering a targeted therapeutic option.

GNH USA supplies Lapatinib Al as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. Its distribution follows strict quality standards, ensuring consistent product integrity for clinical use across multiple regions.

Lapatinib is used to target HER2‑positive cancers, a subset of solid tumors driven by overexpression of the HER2 receptor.

- HER2‑positive metastatic breast cancer: slows disease progression and may improve overall survival. - HER2‑positive gastric cancer: reduces tumor growth and extends progression‑free intervals.

Common Side Effects: - Diarrhea: frequent loose stools that may require supportive care. - Rash: skin irritation often appearing on the trunk or limbs. - Nausea: feeling of sickness that can affect appetite. - Fatigue: persistent tiredness not relieved by rest.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Interstitial lung disease: inflammation of lung tissue that can cause breathing difficulty.

Before initiating therapy, clinicians should consider the following precautions: - Liver function monitoring: assess hepatic enzymes regularly. - Cardiac assessment: evaluate baseline and periodic cardiac function. - QT interval evaluation: avoid use in patients with known QT prolongation. - Severe hepatic impairment: contraindicated or requires dose adjustment. - Diarrhea management: monitor and treat promptly to prevent dehydration. - Store at below 25°C: keep in the original pack, protect from moisture.

Lapatinib may interact with several medicines; careful review is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): can markedly increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin): can reduce efficacy by lowering drug levels. - Antacids containing aluminum or magnesium: may decrease absorption.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for potential anticoagulant effect changes. - Digoxin: observe serum levels for possible toxicity. - Concurrent HER2‑targeted antibodies (e.g., trastuzumab): may increase risk of cardiac events.